Chambers v. Ortho Pharmaceutical Corp.

383 So. 2d 46
CourtLouisiana Court of Appeal
DecidedMarch 25, 1980
DocketNo. 7711
StatusPublished
Cited by4 cases

This text of 383 So. 2d 46 (Chambers v. Ortho Pharmaceutical Corp.) is published on Counsel Stack Legal Research, covering Louisiana Court of Appeal primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Chambers v. Ortho Pharmaceutical Corp., 383 So. 2d 46 (La. Ct. App. 1980).

Opinion

DOMENGEAUX, Judge.

Upon application by Ortho Pharmaceutical Corporation, this Court issued a supervisory writ1 to decide whether the trial court erred in ordering Ortho to further respond to certain interrogatories propounded by plaintiff. Based solely on information contained in Ortho’s writ application, this Court granted the writ. Our primary concern was that the trial court order compelling additional answers, requiring Ortho to pay costs, and possibly subjecting Ortho to an imminent contempt citation for refusing to comply with the trial court’s order, may have been oppressive or unreasonable. Since such an order is not appeal-able, Ortho’s only remedy was to apply for supervisory writs. Advertiser, Division of Independent, Inc. v. Tubbs, 199 So.2d 426 (La.App. 3rd Cir. 1967).2

[48]*48After a careful review of the events preceding this pretrial impasse, and of the applicable law, we conclude that the writ was providently granted and that Ortho is entitled to relief notwithstanding its rather questionable pre-trial tactics.

Familiarity with the chronology of events will facilitate an understanding of our resolution of the issues. Plaintiff, Charles L. Chambers, filed a wrongful death action against Ortho and other defendants on November 14, 1978. On September 7, 1979, plaintiff mailed 63 interrogatories to Ortho to answer. Twenty-three days later, on October 1, 1979, Ortho motioned the court for an extension of time within which to answer and/or object to the interrogatories. The motion was signed by Judge Bond, but was revoked by him later the same day (October l).3 Undaunted by this minor setback, Ortho, one week later (October 8), petitioned another judge from the same district (Judge King) with a similar request for an extension of time. Judge King, apparently unaware of Judge Bond’s recent refusal of the same request, signed the motion. On October 12th, Ortho was ordered to show cause on October 30th why the October 8th order should not be recalled. Before this rule was heard, however, Ortho, on October 25th answered most of the interrogatories and objected to the remainder as being unduly burdensome .and beyond the scope of discovery.

On October 30th, the October 8th order granting Ortho an extension of time within which to answer or object was set aside. On November 2nd, defendant was ordered to show , cause why it should not be required to answer fully all interrogatories and pay all reasonable expenses imposable under La.C.C.P. Article 1469. Hearing on this rule was held January 3,1980, at which time Ortho was ordered to answer fully and completely interrogatories numbered 32, 33, 35,55, 56, and 60 (all of which had previously been answered or objected to on October 25) within ten days of January 3rd. This judgment was signed by Judge King on January 28th, fifteen days after defendant was supposed to have complied with the rule.4

On February 5th, plaintiff filed a rule to impose sanctions and contempt as provided by La.C.C.P. Article 1471, due to defendant’s failure to comply with the court order. Hearing was fixed for February 15th. This writ was applied for and granted before the February 15th hearing was held. The January 3rd order and the rule for La.C.C.P. Article 1471 sanctions were stayed by this Court pending determination of the writ. The matter was submitted on March 4, 1980.

Defendant Ortho asks this Court to relieve it of the burden of further answering interrogatories numbered 32, 33, 35, 55, 56, and 60. Defendant claims that interrogatories 32, 33, 35, and 60 have already been fully answered; and that 55 and 56 are overly broad, are beyond the scope of discovery, and are completely answerable only at great expense to defendant. The subject interrogatories and the answers and/or objections given by Ortho are quoted in full below:

“Interrogatory No. 32:
Is Ortho-Novum 1/50-28 recommended by the manufacturer to be used to treat dysfunctional uterine bleeding, in a pa[49]*49tient 17 years of age, with a history of renal disease (Hematuria)?
XXXII. [32]
Defendant, Ortho Pharmaceutical Corporation, is the manufacturer of an ethical drug and not a treating physician and, therefore, leaves such matters to the professional judgment of the treating physician.
Interrogatory No. 33:
If the product is ever used for the treatment of dysfunctional uterine bleeding, please state:
a) The conditions when it may be used,
b) The dosage, or what factors determine dosage,
c) Preliminary studies by the physician, if any,
d) Precautions to be given to the patient by the physician,
e) Follow-up studies, if any; by .the physician,
f) For what period of time,
g) Contraindications to be wary of after the initial dosage.
XXXIII. [33]
See answer to XXXII. [32]
Interrogatory No. 35:
State in detail what facts, tests, preliminary work-up or history should the doctor utilize prior to placing a 17 year old female on this product (Ortho-Novum) solely for the purpose of regulating her' menses.
XXXV. [35]
See answer to XXXII. [32]
Interrogatory No. 55:
Please list in chronological order the names and addresses of all persons who have received or claim to have received injuries resulting or suspected by them or their physician to have resulted in the use of Ortho-Novum or similar products manufactured by you and with respect to each please state:
a) The nature of the injury claimed,
b) The date the defendant first received notice of the injury,
c) The name and address of the attending physician involved.
LV. [55]
This information is available in the NDA which is on file with the Food & Drug Administration in Washington, D. C., as well as with the Ortho Pharmaceutical Corporation, as more specifically set out in the attached NDA answer.
NDA ANSWER [to 55 and 56]
Defendant objects to this interrogatory in that it is overly broad and unduly burdensome. With respect to the New Drug Application for the relevant time period, for the dosage allegedly used by the plaintiff, and with respect to the injuries allegedly sustained by plaintiff, defendant states that whatever information Ortho has concerning this interrogatory is disclosed in defendant Ortho’s New Drug Application filed with the Food and Drug Administration, United States Department of Health, Education and Welfare, Washington, D. C. and numerous volumes of correspondence between defendant Or-tho and the Food and Drug Administration subsequent thereto.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Testa Distributing Co., Inc. v. Tarver
584 So. 2d 300 (Louisiana Court of Appeal, 1991)
Holloway v. City of Alexandria
506 So. 2d 234 (Louisiana Court of Appeal, 1987)
Wallace v. Pan American Fire & Cas. Co.
386 So. 2d 158 (Louisiana Court of Appeal, 1980)

Cite This Page — Counsel Stack

Bluebook (online)
383 So. 2d 46, Counsel Stack Legal Research, https://law.counselstack.com/opinion/chambers-v-ortho-pharmaceutical-corp-lactapp-1980.